Citation: Ming Zhou, Xiaoqin Yin, Yi Yang, Jian Li, Peng Liu, Jinhui Yang, Pengfei Xu, Shuo Hu, Feifei An. An Evans blue-modified melanin-targeting theranostic agent for improved PET imaging and radionuclide therapy of malignant melanoma[J]. Chinese Chemical Letters, ;2026, 37(12): 112361. doi: 10.1016/j.cclet.2026.112361 shu

An Evans blue-modified melanin-targeting theranostic agent for improved PET imaging and radionuclide therapy of malignant melanoma

Ming Zhou ^{a, b, 1} ,
Xiaoqin Yin ^{b, f, 1} ,
Yi Yang ^b ,
Jian Li ^b ,
Peng Liu ^b ,
Jinhui Yang ^b ,
Pengfei Xu ^{c, *,} ,
Shuo Hu ^{b, d, e, *,} ,
Feifei An ^{a, *,}

a.
School of Public Health, Health Science Center, Xi’an Jiaotong University, Xi’an 710061, China
b.
Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha 410008, China
c.
Department of Nuclear Medicine, The First Afliated Hospital of Weifang Medical University, Weifang 261031, China
d.
National Clinical Research Center for Geriatric Disorders (Xiangya), Changsha 410008, China
e.
Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha 410008, China
f.
Department of Nuclear Medicine, Changsha Central Hospital Affiliated to Nanhua University, Changsha 410004, China

pengfeixucsu@outlook.com

hushuo2018@163.com

anfeifei@xjtu.edu.cn

Received Date: 18 September 2025
Revised Date: 25 December 2025
Accepted Date: 3 January 2026
Available Online: 5 January 2026

Figures(4)

Melanin is the characteristic product of the vast majority of melanomas which is the most lethal and invasive type of skin cancer. We synthesized a new probe that target melanin, H-3, and its variant that connected to the Evans blue, H-3-EB, were radiolabeled with [⁶⁸Ga]Ga and [¹⁷⁷Lu]Lu, respectively. Both [⁶⁸Ga]Ga-H-3 and [⁶⁸Ga]Ga-H-3-EB have favorable affinity and specificity for melanin, and good diagnostic efficacy for melanoma. [¹⁷⁷Lu]Lu-H-3-EB showed a more pronounced therapeutic effect than [¹⁷⁷Lu]Lu-H-3 in B16 tumors since its extended effective half life in vivo by its ability binding to albumin. [⁶⁸Ga]Ga-H-3-EB was well tolerated by malignant melanoma (MM) patients, and detected all primary melanoma lesions and lymph node metastases. This suggests that [¹⁷⁷Lu]Lu-H-3-EB could become a highly promising therapeutic option for patients with advanced melanoma.
- Melanoma,
- PET/CT,
- Evans blue,
- First-in-human study,
- Radionuclide therapy,
- Melanin,
- Molecular image
1. [1]
  J.Y. Wang, E.B. Wang, S.M. Swetter, JAMA 329 (2023) 948. doi: 10.1001/jama.2022.24888
2. [2]
  K.D. Miller, L. Nogueira, T. Devasia, et al., CA Cancer J. Clin. 72 (2022) 409–436. doi: 10.3322/caac.21731
3. [3]
  C. Karimkhani, B.Y. Reddy, R.P. Dellavalle, S. Sundararajan, BMJ 359 (2017) j5174. doi: 10.1136/bmj.j5174
4. [4]
  J. Larkin, V. Chiarion-Sileni, R. Gonzalez, et al., N. Engl. J. Med. 381 (2019) 1535–1546. doi: 10.1056/nejmoa1910836
5. [5]
  K.T. Flaherty, C. Robert, P. Hersey, et al., N. Engl. J. Med. 367 (2012) 107–114. doi: 10.1056/NEJMoa1203421
6. [6]
  J.J. Luke, K.T. Flaherty, A. Ribas, G.V. Long, Nat. Rev. Clin. Oncol. 14 (2017) 463–482. doi: 10.1038/nrclinonc.2017.43
7. [7]
  G.A. McArthur, P.B. Chapman, C. Robert, et al., Lancet Oncol. 15 (2014) 323–332. doi: 10.1016/S1470-2045(14)70012-9
8. [8]
  P.A. Ascierto, G.A. McArthur, B. Dréno, et al., Lancet Oncol. 17 (2016) 1248–1260. doi: 10.1016/S1470-2045(16)30122-X
9. [9]
  S. Espenel, A. Vallard, C. Rancoule, et al., Crit. Rev. Oncol. Hematol. 110 (2017) 13–19. doi: 10.1016/j.critrevonc.2016.12.003
10. [10]
  T. Ertveldt, L. De Beck, K. De Ridder, et al., Mol. Cancer Ther. 21 (2022) 1136–1148. doi: 10.1158/1535-7163.mct-21-0791
11. [11]
  L. Xie, M. Hanyu, M. Fujinaga, et al., J. Nucl. Med. 61 (2020) 242–248. doi: 10.2967/jnumed.119.230946
12. [12]
  J. Li, J. Wang, B. Li, et al., Chin. Chem. Lett. 37 (2026) 111878. doi: 10.1016/j.cclet.2025.111878
13. [13]
  Y. Liu, J. Liang, M. Zheng, et al., Chin. Chem. Lett. 36 (2025) 110317. doi: 10.1016/j.cclet.2024.110317
14. [14]
  J. Malcolm, N. Falzone, B.Q. Lee, K.A. Vallis, Cancers 11 (2019) 268. doi: 10.3390/cancers11020268
15. [15]
  B.M. Bavelaar, B.Q. Lee, M.R. Gill, et al., Front. Pharmacol. 9 (2018) 996. doi: 10.3389/fphar.2018.00996
16. [16]
  W. Beaino, J.R. Nedrow, C.J. Anderson, Mol. Pharm. 12 (2015) 1929–1938. doi: 10.1021/mp5006917
17. [17]
  Y. Miao, N.K. Owen, D.R. Fisher, et al., J. Nucl. Med. 46 (2005) 121–129.
18. [18]
  F. Salazar-Onfray, M. López, A. Lundqvist, et al., Br. J. Cancer 87 (2002) 414–422. doi: 10.1038/sj.bjc.6600441
19. [19]
  Y. Miao, M. Hylarides, D.R. Fisher, et al., Clin. Cancer Res. 11 (2005) 5616–5621. doi: 10.1158/1078-0432.CCR-05-0619
20. [20]
  Y. Miao, D. Whitener, W. Feng, et al., Bioconjug. Chem. 14 (2003) 1177–1184. doi: 10.1021/bc034069i
21. [21]
  A.A. Rosenkranz, T.A. Slastnikova, M.O. Durymanov, A.S. Sobolev, Biochemistry 78 (2013) 1228–1237.
22. [22]
  E. Wee, R. Wolfe, C. McLean, et al., J. Am. Acad. Dermatol. 79 (2018) 645–651.e4. doi: 10.1016/j.jaad.2018.04.045
23. [23]
  P.K. Garg, R. Nazih, Y. Wu, et al., J. Nucl. Med. 58 (2017) 827–832. doi: 10.2967/jnumed.116.184564
24. [24]
  F. Degoul, M. Borel, N. Jacquemot, et al., Int. J. Cancer 133 (2013) 1042–1053. doi: 10.1002/ijc.28103
25. [25]
  E.B. Ehlerding, X. Lan, W. Cai, Theranostics 8 (2018) 812–814. doi: 10.7150/thno.24183
26. [26]
  Z. Liu, X. Chen, Chem. Soc. Rev. 45 (2016) 1432–1456. doi: 10.1039/C5CS00158G
27. [27]
  J. Lau, O. Jacobson, G. Niu, et al., Bioconjug. Chem. 30 (2019) 487–502. doi: 10.1021/acs.bioconjchem.8b00919
28. [28]
  H. Chen, O. Jacobson, G. Niu, et al., J. Nucl. Med. 58 (2017) 590–597. doi: 10.2967/jnumed.116.182097
29. [29]
  H. Feng, X. Xia, C. Li, et al., Eur J. Nucl. Med. Mol. Imaging 43 (2016) 113–122. doi: 10.1007/s00259-015-3134-2
30. [30]
  T. Wang, P. Xu, J. Fang, et al., Mol. Pharm. 20 (2023) 1015–1024. doi: 10.1021/acs.molpharmaceut.2c00745
31. [31]
  A. Pyo, D.Y. Kim, H. Kim, et al., Proc. Natl. Acad. Sci. U. S. A. 117 (2020) 12991–12999. doi: 10.1073/pnas.1922313117
32. [32]
  C.C. Chen, Y.Y. Chen, Y.H. Lo, et al., Int. J. Mol. Sci. 21 (2020) 6597. doi: 10.3390/ijms21186597
33. [33]
  Y. Miao, N.K. Owen, D. Whitener, et al., Int. J. Cancer 101 (2002) 480–487. doi: 10.1002/ijc.10640
34. [34]
  L. Rbah-Vidal, A. Vidal, E.M. Billaud, et al., Neoplasia 19 (2017) 17–27. doi: 10.1016/j.neo.2016.11.001
35. [35]
  M. Bonnet-Duquennoy, J. Papon, F. Mishellany, et al., Int. J. Cancer 125 (2009) 708–716. doi: 10.1002/ijc.24413
36. [36]
  R. Tian, O. Jacobson, G. Niu, et al., Theranostics 8 (2018) 735–745. doi: 10.7150/thno.23491
37. [37]
  M. Xu, P. Zhang, J. Ding, et al., J. Nucl. Med. 63 (2022) 952–958. doi: 10.2967/jnumed.121.262533
38. [38]
  Q. Liu, Y. Cheng, J. Zang, et al., Eur. J. Nucl. Med. Mol. Imaging 47 (2020) 947–957. doi: 10.1007/s00259-019-04530-1
39. [39]
  Z. Wang, O. Jacobson, R. Tian, et al., Bioconjug. Chem. 29 (2018) 2309–2315. doi: 10.1021/acs.bioconjchem.8b00292
40. [40]
  J.A. Violet, J.L. Dearling, A.J. Green, et al., Br. J. Cancer 99 (2008) 632–638. doi: 10.1038/sj.bjc.6604511
41. [41]
  D. Delbeke, R.E. Coleman, M.J. Guiberteau, et al., J. Nucl. Med. 47 (2006) 885–895.
42. [42]
  X. Ma, S. Wang, S. Wang, et al., J. Nucl. Med. 60 (2019) 16–22. doi: 10.2967/jnumed.118.209643
43. [43]
  X. Xu, L. Yuan, L. Yin, et al., Mol. Pharm. 14 (2017) 3896–3905. doi: 10.1021/acs.molpharmaceut.7b00607
44. [44]
  X. Zhang, M. Li, Y. Gai, et al., J. Nucl. Med. 63 (2022) 1537–1543. doi: 10.2967/jnumed.121.263179
1. [1]
  Ling Yang , Min Ren , Jie Wang , Liming He , Shanshan Wu , Shuai Yang , Wei Zhao , Hao Cheng , Xiaoming Zhou , Maling Gou . A non-viral gene therapy for melanoma by staphylococcal enterotoxin A. Chinese Chemical Letters, 2024, 35(5): 108822-. doi: 10.1016/j.cclet.2023.108822
2. [2]
  Dexuan Xiao , Tianyu Chen , Tianxu Zhang , Sirong Shi , Mei Zhang , Xin Qin , Yunkun Liu , Longjiang Li , Yunfeng Lin . Transdermal treatment for malignant melanoma by aptamer-modified tetrahedral framework nucleic acid delivery of vemurafenib. Chinese Chemical Letters, 2024, 35(4): 108602-. doi: 10.1016/j.cclet.2023.108602
3. [3]
  Zheyi Li , Xiaoyang Liang , Zitong Qiu , Zimeng Liu , Siyu Wang , Yue Zhou , Nan Li . Ion-interferential cell cycle arrest for melanoma treatment based on magnetocaloric bimetallic-ion sustained release hydrogel. Chinese Chemical Letters, 2024, 35(11): 109592-. doi: 10.1016/j.cclet.2024.109592
4. [4]
  Yang Liu , Jing Liang , Mengzhu Zheng , Haoze Song , Lixia Chen , Hua Li . PD-L1/SHP2 dual PROTACs inhibit melanoma by enhancing T-cell killing activity. Chinese Chemical Letters, 2025, 36(6): 110317-. doi: 10.1016/j.cclet.2024.110317
5. [5]
  Jing Li , Jie Wang , Bingqian Li , Meng Long , Xiumei Liu , Dengxuan Mao , Patrick Pan , Ying Liu , Zimei Wu , Yaqi Lyu , Nianping Feng . Engineering a garlic-derived nanovesicle/microneedle system to boost melanoma immunotherapy through self-amplifying cell death activation and immune remodelling. Chinese Chemical Letters, 2026, 37(8): 111878-. doi: 10.1016/j.cclet.2025.111878
6. [6]
  Kaiyue Yang , Yifan Zhang , Shamei Luo , Chenxi Yu , Lin Chen , Qingyu Yu , Chenlu Huang , Guilei Ma , Linhua Zhang , Dunwan Zhu . Multifunctional nanoadjuvants-aided synergistic photothermal-immunotherapy of tumor. Chinese Chemical Letters, 2026, 37(4): 112324-. doi: 10.1016/j.cclet.2025.112324
7. [7]
  Yongzhi Wu , Rong He , Bowen Tan , Longjiang Li , Jinfeng Liao . An injectable hydrogel for chemodynamic therapy-induced ferroptosis in malignant melanoma. Chinese Chemical Letters, 2026, 37(3): 111339-. doi: 10.1016/j.cclet.2025.111339
8. [8]
  Yu Qin , Mingyang Huang , Chenlu Huang , Hannah L. Perry , Linhua Zhang , Dunwan Zhu . O₂-generating multifunctional polymeric micelles for highly efficient and selective photodynamic-photothermal therapy in melanoma. Chinese Chemical Letters, 2024, 35(7): 109171-. doi: 10.1016/j.cclet.2023.109171
9. [9]
  Ge Ma , Zhen Shen , Kin Shing Chan . 黑色素瘤暗滋生疫苗利刃破坚盾. University Chemistry, 2026, 41(9): 264-269. doi: 10.12461/PKU.DXHX202509006
10. [10]
  Qiangqiang Zhou , Lili Sun , Yu-Jie Guo , Bo Zhou , Chunfang Zhang , Sen Xin , Le Yu , Gaohong Zhai . First-principles study on the electrochemical properties of Na-ion-intercalatable heterostructures formed by transitional metal dichalcogenides and blue phosphorus. Chinese Chemical Letters, 2025, 36(7): 110187-. doi: 10.1016/j.cclet.2024.110187
11. [11]
  Di Zhang , Xu He , Xiaoying Kang , Xue Meng , Ji Qi , Zhifang Wu , Ningbo Li . A photo-accelerated nanoplatform for image-guided synergistic chemo-photodynamic therapy. Chinese Chemical Letters, 2025, 36(12): 110942-. doi: 10.1016/j.cclet.2025.110942
12. [12]
  Botao QU , Qian WANG , Xiaogang NING , Yuxin ZHOU , Ruiping ZHANG . Deeply penetrating photoacoustic imaging in tumor tissues based on dual-targeted melanin nanoparticle. Chinese Journal of Inorganic Chemistry, 2024, 40(5): 1025-1032. doi: 10.11862/CJIC.20230416
13. [13]
  Zhengkun QIN , Lixin BAO , Yunkai ZHANG , Lin CUI , Jinyu WANG , Yuhao WANG , Mingxing SONG . Theoretical study on the thermally activated delayed fluorescence, and efficiency roll-off characteristics of a series of blue and blue-green Ir(Ⅲ) complexes. Chinese Journal of Inorganic Chemistry, 2026, 42(2): 365-374. doi: 10.11862/CJIC.20250222
14. [14]
  Gaoyan Chen , Chaoyue Wang , Juanjuan Gao , Junke Wang , Yingxiao Zong , Kin Shing Chan . Heart to Heart: Exploring Cardiac CT. University Chemistry, 2024, 39(9): 146-150. doi: 10.12461/PKU.DXHX202402011
15. [15]
  Yueru Wei , Qi Miao , Miaomiao Zhang , Wenying Zhang , Mengxiao Shi , Rui Liu , Jingjing Su , Pengchao Sun , Yongxing Zhao . PtCu nanozyme integrating single atom Pt and Pt subnanoclusters for the sustained treatment of cutaneous melanoma. Chinese Chemical Letters, 2025, 36(12): 111164-. doi: 10.1016/j.cclet.2025.111164
16. [16]
  Ying Sun , Minglong Chen , Ying Chen , Wanchen Zhao , Yanping Fu , Zhengwei Huang , Chao Lu , Chuanbin Wu , Xin Pan , Guilan Quan . Dissolving microneedle-assisted in situ cancer vaccine combined with cytolytic peptide for anti-melanoma immunotherapy. Chinese Chemical Letters, 2025, 36(12): 110908-. doi: 10.1016/j.cclet.2025.110908
17. [17]
  Shaohua Zhang , Xiaojuan Dai , Wei Hao , Liyao Liu , Yingqiao Ma , Ye Zou , Jia Zhu , Chong-an Di . A first-principles study of the Nernst effect in doped polymer. Chinese Chemical Letters, 2024, 35(12): 109837-. doi: 10.1016/j.cclet.2024.109837
18. [18]
  Hongqin Chu , Liyang Li , Fan Yang , Shujuan Li , Jiayao Wang , Shulai Lei , Jinbo Sun , Ke Xu , Xinyue Xiong , Zhenpeng Hu . Characterization of intrinsic defects and their effects on carrier lifetime in CdTeSe: First principles and non-adiabatic molecular dynamics simulations. Chinese Chemical Letters, 2026, 37(9): 111490-. doi: 10.1016/j.cclet.2025.111490
19. [19]
  Zhaoyong Kang , Shen Li , Yan Li , Jingfeng Song , Yangrui Peng , Yihua Chen . Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024). Chinese Chemical Letters, 2025, 36(7): 110447-. doi: 10.1016/j.cclet.2024.110447
20. [20]
  Wei Zhou , Di He , Ning Liu , Ying Li , Wenzhao Han , Weiping Zhou , Siyu Zhang , Cong Yu . A PDI-based NIR-Ⅱ fluorescence imaging guided molecular phototheranostic platform for GSH-triggered gas therapy, mild photothermal therapy and NIR-activated photodynamic therapy. Chinese Chemical Letters, 2025, 36(11): 110854-. doi: 10.1016/j.cclet.2025.110854

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(4)
HTML views(0)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142